CROSSTREE

Ascent and PharmaLex Merge to Expand Clinical Development Services in Asia



APAC is the world's fastest growing pharmaceuticals market: pharma sales in Japan alone are expected to exceed \$150 billion by the end of 2022.To access this demand, manufacturers require in-market CROs to execute their clinical development programs. At the same time, emerging APAC-based pharma companies must utilize established global CROs to expand their reach to international markets.

Founded in 2017, Ascent Development Services (Ascent) works with emerging biopharma companies to understand and overcome differences in medical practice, culture, and language in order to achieve the optimal strategic and operational integration of Asia into global drug development programs. Headquartered in Tokyo, Ascent employs staff across China, Korea, Malaysia, the Philippines, Taiwan, Thailand, and Vietnam and provides a balance of country-specific knowledge mixed with strategic advice from a global drug development perspective. The company's expertise and pan-Asian infrastructure made it the perfect complement to PharmaLex's broad CRO services portfolio and existing US and EU footprint.

Crosstree's deep sector expertise helped Ascent identify PharmaLex as the ideal partner to expand its access to international clients while expanding PharmaLex's service scope and global footprint in Asia.

Crosstree helps clients develop and execute growth strategies that maximize synergies for all stakeholders.

CROSSTREE

ABOUT ASCENT



Ascent's experts work with emerging biopharma to understand and overcome differences in medical practice, culture, and language to achieve optimal integration of Asia into global drug development thus enabling accelerated entry into Asia's rapidly growing markets

CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER — BY THE NUMBERS AND BEYOND — IS CROSSTREE'S SPECIALTY.

ABOUT PHARMALEX



PharmaLex is a leading provider of specialized services for the pharma, biotech and medtech industries. We guide you from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technologyenabled solutions to support you through the entire product lifecycle. We deliver exceptional results going above and beyond the standard to deliver tailor-made solutions worldwide. The PharmaLex Group now has over 2,300 employees, with 53 offices in 25 countries and more than 1,000 satisfied clients worldwide. Crosstree's proven track record of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



jason.layton@crosstreecapital.com 813-578-7109